Recently we added Dr. Joe Duarte to our research team at Smart Tech Investor, and have been very impressed with his insight and analysis. Although we realize the biotech sector has appreciated considerably during the past year and may be due for a correction, we feel the long term upside… Read More
Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.
Analyst Articles
Evaluating the latest gloomy forecast. Read More
As explained in this week’s edition of Smart Tech 50 Weekly Movers, we are adding the following holdings to the STI Equity Trades Portfolio:STOCKRepligen (RGEN)Emergent BioSolutions (EBS)Medivation (MDVN)ETFiShares Nasdaq Biotechnology ETF (IBB)PowerShares Dynamic Biotech & Genome ETF (PBE)… Read More
As explained in this week’s edition of Smart Tech 50 Weekly Movers, we are adding the following holdings to the STI Equity Trades Portfolio:STOCKRepligen (RGEN)Emergent BioSolutions (EBS)Medivation (MDVN)ETFiShares Nasdaq Biotechnology ETF (IBB)PowerShares Dynamic Biotech & Genome ETF (PBE)… Read More
Equity Trades Portfolio Updateby Joe Duarte, M.D.Buy AlertsEarnings UpdateNews Update: It’s ASCO Conference SeasonM & A UpdateThe biotech sector rebounded on the week that ended on May 8th. Behind another merger announcement and some mixed economic news, the worries about the Federal Reserve raising interest rates… Read More
Equity Trades Portfolio Updateby Joe Duarte, M.D.Buy AlertsEarnings UpdateNews Update: It’s ASCO Conference SeasonM & A UpdateThe biotech sector rebounded on the week that ended on May 8th. Behind another merger announcement and some mixed economic news, the worries about the Federal Reserve raising interest rates… Read More
But it's not the first time he’s done it, and may not be the last. Read More
The Nasdaq Biotech Index (NBI) gave back nearly half of the year’s gains from April 23rd to April 30th. Thus, a bounce is clearly in the offing and is one to watch carefully. By the same token if Friday’s (May 1) bounce fizzles in the not too distant future, we… Read More
The Nasdaq Biotech Index (NBI) gave back nearly half of the year’s gains from April 23rd to April 30th. Thus, a bounce is clearly in the offing and is one to watch carefully. By the same token if Friday’s (May 1) bounce fizzles in the not too distant future, we… Read More
Latest GDP figure is a day late and a dollar short. Read More